Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease
NCT02322021Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2014
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elenbecestat in Alzheimer's disease (AD) (8 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Treatment Emergent Adverse Events up to 21 months, Serious Adverse Events up to 21 months and 3 more. Started Nov 2014; status: terminated.
02
Drugs
elenbecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02322021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322021.